Table 2. Demographic features of adult celiac disease (CD) patients and controls.
| Refractory CD | Treated CD | Healthy controls | ||
| Number | 14 | 13 | 14 | |
| Age in years, mean (SD) | 60.5 (11.0) | 46.1 (14.7) | 36.5 (11.5) | |
| Male, n (%) | 6 (43%) | 6 (55%) | 4 (29%) | |
| Positive antibodies | ||||
| (EmA, tTG), n (%) | 1 (7%)* | 0 (0%) | 0 (0%) | |
| Marsh score, n (%) | Marsh 0 | 6 (43%) | 7 (54%) | not determined |
| Marsh 1 | 3 (21%) | 6 (46%) | ||
| Marsh 2 | 0 (0%) | |||
| Marsh 3A | 2 (14%) | |||
| Marsh 3B | 2 (14%) | |||
| Marsh 3C | 1 (7%) | |||
| Diagnosis, n (%) | RCD 1 | 7 (50%) | ||
| RCD 2 | 5 (35%) | |||
| EATL | 3 (21%) | |||
| Treatment, n (%) | No | 0 (0%) | 0 (0%) | 14 (100%) |
| GFD | 13 (93%) | 13 (100%) | ||
| Immunoregulatory drugs | 9 (64%) | 0 (0%) | ||
| Unknown | 1 (7%) | 0 (0%) |
CD, celiac disease; EmA, anti-endomysial antibodies; tTG anti-tissue transglutaminase antibodies; RCD, refractory celiac disease; EATL, enteropathy-associated T cell lymphoma; GFD, gluten free diet. All patients were tested for anti-tissue transglutaminase and anti-endomysial antibodies. * This patient was positive for anti-tissue transglutaminase antibodies.